Show simple item record

dc.contributor.authorSzczepiorkowski, Zbigniew M.
dc.contributor.authorWinters, Jeffrey L.
dc.contributor.authorBandarenko, Nicholas
dc.contributor.authorKim, Haewon C.
dc.contributor.authorLinenberger, Michael L.
dc.contributor.authorMarques, Marisa B.
dc.contributor.authorSarode, Ravindra
dc.contributor.authorSchwartz, Joseph
dc.contributor.authorWeinstein, Robert
dc.contributor.authorShaz, Beth H.
dc.date2022-08-11T08:11:00.000
dc.date.accessioned2022-08-23T17:28:33Z
dc.date.available2022-08-23T17:28:33Z
dc.date.issued2010-06-03
dc.date.submitted2010-07-01
dc.identifier.citationJ Clin Apher. 2010;25(3):83-177.
dc.identifier.issn1098-1101
dc.identifier.pmid20568098
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50108
dc.description.abstractThe American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (fourth edition), the subcommittee has incorporated systematic review and evidence-based approach in the grading and categorization of indications. This Fifth ASFA Special Issue has further improved the process of using evidence-based medicine in the recommendations by refining the category definitions and by adding a grade of recommendation based on widely accepted GRADE system. The concept of a fact sheet was introduced in the Fourth edition and is only slightly modified in this current edition. The fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis. The article consists of 59 fact sheets devoted to each disease entity currently categorized by the ASFA as category I through III. Category IV indications are also listed.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20568098&dopt=Abstract">Link to article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1002/jca.20240
dc.subjectBlood Component Removal
dc.subjectEvidence-Based Practice
dc.subjectPractice Guideline
dc.subjectPlasma Exchange
dc.subjectLeukapheresis
dc.subjectPhotopheresis
dc.subjectHemic and Immune Systems
dc.subjectOther Medical Specialties
dc.titleGuidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.
dc.typeJournal Article
dc.source.journaltitleJournal of Clinical Apheresis
dc.source.volume25
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/transfusion_pp/7
dc.identifier.contextkey1378272
html.description.abstract<p>The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (fourth edition), the subcommittee has incorporated systematic review and evidence-based approach in the grading and categorization of indications. This Fifth ASFA Special Issue has further improved the process of using evidence-based medicine in the recommendations by refining the category definitions and by adding a grade of recommendation based on widely accepted GRADE system. The concept of a fact sheet was introduced in the Fourth edition and is only slightly modified in this current edition. The fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis. The article consists of 59 fact sheets devoted to each disease entity currently categorized by the ASFA as category I through III. Category IV indications are also listed.</p>
dc.identifier.submissionpathtransfusion_pp/7
dc.contributor.departmentDepartment of Medicine, Division of Transfusion Medicine


This item appears in the following Collection(s)

Show simple item record